2024-09-01 - Analysis Report
## Gilead Sciences (GILD) Stock Analysis Report

**Company Overview:** Gilead Sciences is a biopharmaceutical company that develops and commercializes medicines for a variety of medical conditions, including HIV/AIDS, hepatitis B and C, and oncology.

**Performance Analysis:**

**1. Relative Performance:**

* **Cumulative Return:** GILD has a cumulative return of 14.51% compared to the S&P 500 (VOO) with a return of 89.66%. This signifies a significant underperformance of GILD against the benchmark.
* **Relative Lag:** GILD currently lags the S&P 500 by -60.83%. This puts it at the 16.68% percentile of historical relative performance, suggesting that it has underperformed the benchmark for the majority of its history.

**2. Recent Price Action:**

* **Closing Price:** $79.0
* **5-Day Moving Average:** $78.19
* **20-Day Moving Average:** $75.47
* **60-Day Moving Average:** $71.78
* The current price is slightly above all moving averages, indicating potential short-term upside momentum.

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 87.42 -  This indicates the stock is currently in overbought territory, suggesting a potential correction in the near term.
* **PPO (Price Momentum Oscillator):** 0.4 - The positive PPO value suggests a short-term upward trend.
* **Delta_Previous_Relative_Divergence:** -4.8 - The negative value indicates a recent decline in relative performance, suggesting a potential weakening of the bullish momentum.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 1.29 | 6.95 B$ |
| 2024-05-08 | -3.34 | 6.69 B$ |
| 2023-11-07 | 1.75 | 7.05 B$ |
| 2023-08-04 | 0.84 | 6.60 B$ |
| 2024-08-08 | 0.84 | 6.60 B$ |

The most recent earnings report (2024-08-08) shows an EPS of 1.29 and revenue of 6.95 B$, exceeding analyst expectations. While this indicates strong performance, the stock price has not fully reacted to the positive earnings beat.

**5. Overall Analysis:**

GILD's current performance indicates a stock that is underperforming the benchmark market. While the recent earnings report shows a positive outlook, the overbought technical indicators suggest a potential correction in the near term. Investors should be cautious and monitor the stock's price action closely. 

**6. Recommendations:**

Given the recent performance and technical indicators, investors may consider waiting for a potential correction before entering a position in GILD. Additionally, monitoring the company's future earnings reports and any potential new product launches will provide valuable insights into its long-term outlook.
